Dr. John V. Heymach says the latest findings suggest zongertinib may address an unmet need for patients with HER2-mutant NSCLC. Read more
Research team led by Dr. Shun Lu presents aumolertinib with chemotherapy as an additional first-line treatment option during the 2025 AACR Annual Meeting. Read more
Pioneer in SCLC research Dr. John D. Minna reflected on four decades of advancements in the field during his keynote address at the 2025 Hot Topics in SCLC. Read more
During a recent address at SCLC 2025, Dr. Charles Rudin discussed the progress being made in reducing the incidence of small cell lung cancer and in treating it. Read more
Dr. Nicolas Girard recently presented data that shows prophylactic treatment with oral and topical antibiotics and ceramide-based moisturizer significantly reduced adverse skin events. Read more
Dr. Myung-Ju Ahn said recent data from SAVANNAH show the combination produced a meaningful and durable response in patients whose cancer progressed after osimertinib. Read more
Drs. Chih-Hsin Yang and Pérol reviewed the latest findings and key takeaways during a presentation at the European Lung Cancer Congress. Read more
During his award lecture at the European Lung Cancer Congress, Dr. Kerr said lung cancer treatment has benefited from the bridging of the historical divide between pathology and medical oncology. Read more
During a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies. Read more
Lacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case. Read more